Gilead Sciences (GILD)
(Delayed Data from NSDQ)
$64.92 USD
-0.54 (-0.82%)
Updated May 8, 2024 04:00 PM ET
After-Market: $65.10 +0.18 (0.28%) 7:58 PM ET
4-Sell of 5 4
B Value C Growth D Momentum B VGM
Company Summary
Headquartered in Foster City, CA, Gilead Sciences is a pioneer in developing drugs for the treatment of human immunodeficiency virus (HIV), liver diseases, hematology/oncology diseases and inflammation/respiratory diseases. The company has a strong HIV franchise with key HIV/AIDS therapies like tenofovir alafenamide (TAF)-based products like Genvoya, Odefsey, Descovy, Biktarvy and Truvada. Total sales from the HIV franchise came in at $18.2 billion in 2023, up 6% year over year, driven by strong growth in lead HIV treatment Biktarvy.
Gilead’s liver disease portfolio includes chronic hepatitis C virus (HCV) drugs like Harvoni ...
Company Summary
Headquartered in Foster City, CA, Gilead Sciences is a pioneer in developing drugs for the treatment of human immunodeficiency virus (HIV), liver diseases, hematology/oncology diseases and inflammation/respiratory diseases. The company has a strong HIV franchise with key HIV/AIDS therapies like tenofovir alafenamide (TAF)-based products like Genvoya, Odefsey, Descovy, Biktarvy and Truvada. Total sales from the HIV franchise came in at $18.2 billion in 2023, up 6% year over year, driven by strong growth in lead HIV treatment Biktarvy.
Gilead’s liver disease portfolio includes chronic hepatitis C virus (HCV) drugs like Harvoni and Epclusa, chronic hepatitis B virus drug Vemlidy and Viread, and other chronic hepatitis delta virus (HDV) products. Harvoni and Epclusa have now lost their sheen. For 2023, the liver disease portfolio generated sales of $2.8 billion, down 1% year over year.
Gilead is also looking to build an oncology franchise. Yescarta, the first cell therapy approved for the treatment of adult patients with relapsed or refractory large B-cell lymphoma, has diversified Gilead’s portfolio. Tecartus, another CAR T-cell therapy, was granted accelerated approval in the United States in July for the treatment of relapsed or refractory mantle cell lymphoma. The Cell Therapy Product franchise posted a stellar performance in 2023 with sales of $1.9 billion, up 28% year over year.
Gilead is making inroads in the oncology space with strategic collaborations and acquisitions. It acquired oncology company Immunomedics for approximately $21 billion in 2020, which added the breast cancer drug Trodelvy to its portfolio. Trodelvy, for breast cancer, solidifies its oncology franchise and provides a strong opportunity for growth. Trodelvy’s sales surged 56% from the 2022 level to reach $1.1 billion in 2023, reflecting strong demand in new and existing geographies.
Gilead has a robust late-stage pipeline that bodes well for long-term growth. The company is also working on diversifying and growing its business beyond antivirals into other therapeutic areas. Veklury (remdesivir), for the treatment of COVID-19 patients, generated sales of $2.2 billion in 2023, down 44% year over year due to the evolution of the pandemic.
Total revenues in 2023 came in at $27.1 billion, down from $27.3 billion in 2022.
General Information
Gilead Sciences, Inc
333 LAKESIDE DRIVE
FOSTER CITY, CA 94404
Phone: 650-574-3000
Fax: 650-578-9264
Email: investor_relations@gilead.com
Industry | Medical - Biomedical and Genetics |
Sector | Medical |
Fiscal Year End | December |
Last Reported Quarter | 3/31/2024 |
Exp Earnings Date | 8/1/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | 1.58 |
Current Year EPS Consensus Estimate | 3.75 |
Estimated Long-Term EPS Growth Rate | 13.20 |
Exp Earnings Date | 8/1/2024 |
Price and Volume Information
Zacks Rank | |
Yesterday's Close | 65.46 |
52 Week High | 87.87 |
52 Week Low | 64.33 |
Beta | 0.22 |
20 Day Moving Average | 7,605,896.00 |
Target Price Consensus | 82.55 |
4 Week | -6.41 |
12 Week | -10.98 |
YTD | -19.19 |
4 Week | -6.00 |
12 Week | -15.00 |
YTD | -25.70 |
Shares Outstanding (millions) | 1,245.08 |
Market Capitalization (millions) | 81,502.76 |
Short Ratio | NA |
Last Split Date | 1/28/2013 |
Dividend Yield | 4.71% |
Annual Dividend | $3.08 |
Payout Ratio | 0.76 |
Change in Payout Ratio | 0.33 |
Last Dividend Payout / Amount | 3/14/2024 / $0.77 |
Fundamental Ratios
P/E (F1) | 17.44 |
Trailing 12 Months | 16.24 |
PEG Ratio | 1.32 |
vs. Previous Year | -196.35% |
vs. Previous Quarter | -176.74% |
vs. Previous Year | 5.26% |
vs. Previous Quarter | -6.03% |
Price/Book | 4.67 |
Price/Cash Flow | 7.32 |
Price / Sales | 2.97 |
3/31/24 | 24.34 |
12/31/23 | 38.85 |
9/30/23 | 39.30 |
3/31/24 | 8.36 |
12/31/23 | 13.60 |
9/30/23 | 13.45 |
3/31/24 | 0.98 |
12/31/23 | 1.43 |
9/30/23 | 1.34 |
3/31/24 | 0.72 |
12/31/23 | 1.27 |
9/30/23 | 1.20 |
3/31/24 | 18.52 |
12/31/23 | 31.17 |
9/30/23 | 30.66 |
3/31/24 | 1.76 |
12/31/23 | 20.89 |
9/30/23 | 21.45 |
3/31/24 | 3.91 |
12/31/23 | 25.30 |
9/30/23 | 26.42 |
3/31/24 | 14.02 |
12/31/23 | 18.26 |
9/30/23 | 17.85 |
3/31/24 | 3.15 |
12/31/23 | 3.90 |
9/30/23 | 3.64 |
3/31/24 | NA |
12/31/23 | 1.08 |
9/30/23 | 1.08 |
3/31/24 | NA |
12/31/23 | 51.82 |
9/30/23 | 52.02 |